Editorial
doi: 10.1111/j.1365-2133.2008.08440.x.
Adalimumab: a new alternative biologic agent for chronic plaque psoriasis
- PMID: 18275521
- DOI: 10.1111/j.1365-2133.2008.08440.x
Item in Clipboard
Editorial
Adalimumab: a new alternative biologic agent for chronic plaque psoriasis
Br J Dermatol.
2008 Mar.
No abstract available
Comment on
-
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.Br J Dermatol. 2008 Mar;158(3):549-57. doi: 10.1111/j.1365-2133.2007.08236.x. Epub 2007 Nov 28. Br J Dermatol. 2008. PMID: 18047521 Clinical Trial.
-
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x. Epub 2007 Nov 28. Br J Dermatol. 2008. PMID: 18047523 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
